Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet

Sales Rising Based On Recent IgG4 Disease Approval

 
• By Mandy Jackson
  
Generalized myasthenia gravis is Uplizna's third indication (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip